Merriman Wealth Management LLC boosted its position in shares of Sangamo Therapeutics Inc (NASDAQ:SGMO) by 50.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,000 shares of the biopharmaceutical company’s stock after buying an additional 5,000 shares during the quarter. Merriman Wealth Management LLC’s holdings in Sangamo Therapeutics were worth $159,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of SGMO. Wasatch Advisors Inc. lifted its holdings in Sangamo Therapeutics by 26.8% during the 1st quarter. Wasatch Advisors Inc. now owns 6,437,908 shares of the biopharmaceutical company’s stock worth $61,418,000 after buying an additional 1,359,170 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Sangamo Therapeutics by 459.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,239,110 shares of the biopharmaceutical company’s stock valued at $14,224,000 after acquiring an additional 1,017,573 shares during the last quarter. Bailard Inc. raised its position in shares of Sangamo Therapeutics by 373.0% during the 1st quarter. Bailard Inc. now owns 156,100 shares of the biopharmaceutical company’s stock valued at $1,489,000 after acquiring an additional 123,100 shares during the last quarter. Sector Gamma AS raised its position in shares of Sangamo Therapeutics by 54.1% during the 1st quarter. Sector Gamma AS now owns 238,857 shares of the biopharmaceutical company’s stock valued at $2,279,000 after acquiring an additional 83,897 shares during the last quarter. Finally, Bank of America Corp DE raised its position in shares of Sangamo Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 159,812 shares of the biopharmaceutical company’s stock valued at $1,834,000 after acquiring an additional 46,981 shares during the last quarter. 57.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of SGMO traded up $0.04 during trading hours on Wednesday, reaching $11.48. The stock had a trading volume of 38,557 shares, compared to its average volume of 2,072,304. The company has a current ratio of 3.98, a quick ratio of 3.98 and a debt-to-equity ratio of 0.04. Sangamo Therapeutics Inc has a 52 week low of $6.26 and a 52 week high of $19.25. The company’s 50-day moving average is $11.51. The company has a market cap of $1.30 billion, a P/E ratio of -16.40 and a beta of 2.93.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.09. Sangamo Therapeutics had a negative net margin of 136.73% and a negative return on equity of 28.97%. The business had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $13.58 million. During the same quarter in the prior year, the company earned ($0.17) EPS. The firm’s quarterly revenue was down 18.1% on a year-over-year basis. Equities analysts forecast that Sangamo Therapeutics Inc will post -1.45 earnings per share for the current year.

Several analysts have commented on SGMO shares. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 17th. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a research report on Monday, July 8th. BidaskClub cut shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, ValuEngine upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $13.33.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Article: Hedge Funds Explained

Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).

Institutional Ownership by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.